Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets

This article was originally published in Start Up

Executive Summary

An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.
Advertisement

Related Content

Valuing Early-Stage Pharma Deals
Pharma: Serious About Change?
Pharma: Serious About Change?
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
Celgene Teams Up With Agios In Long-Term Cancer Metabolism Pact
With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene
Building the Next Generation of GPCR-Targeting Drugs
Sirtris Satisfies GSK's M&A Appetite
The Next-Generation Antibody Players

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091916

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel